Patents Examined by Andrew Wang
  • Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
    Patent number: 6417169
    Abstract: This invention relates to oligonucleotides complementary to the IGF-II genes which modulate tumor cell growth in mammals. This invention is also related to methods of using such compounds in inhibiting the growth of tumor cells in mammals. This invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and an effective amount of a compound of this invention.
    Type: Grant
    Filed: April 22, 1999
    Date of Patent: July 9, 2002
    Assignee: Genesense Technologies Inc.
    Inventors: Jim A. Wright, Aiping H. Young, Yoon S. Lee
  • Removal of dye-labeled dideoxy terminators from DNA sequencing reactions
    Patent number: 6414136
    Abstract: This invention provides methods for removing unincorporated fluorescent dye-labeled molecules from a mixture that includes fluorescently-labeled polynucleotides and the unincorporated fluorescent dye-labeled molecules. The methods involve adsorbing the unincorporated fluorescent dye-labeled molecules into a plurality of particles that are made up of one or more porous hydrophobic materials that are encapsulated in a hydrophilic matrix.
    Type: Grant
    Filed: May 3, 2000
    Date of Patent: July 2, 2002
    Assignee: Prolinx, Inc.
    Inventors: Douglas A. Spicer, Karin A. Hughes, Robert J. Kaiser, James E. Mahoney, Amy L. Springer, Mark L. Stolowitz, Carl H. D. Weissman
  • Inducible phosphofructokinase and the Warburg effect
    Patent number: 6413939
    Abstract: There is disclosed a cancer malignancy diagnostic assay comprising obtaining a sample of a body fluid or tissue, performing a sequence identity assay to look for the presence of PFK-2 specific sequences; an anticancer pharmaceutical composition comprising a specific antisense oligonucleotide to the inventive isolated PFK-2 sequence and a pharmaceutically acceptable oligonucleotide carrier; and a method for finding therapeutically active anti-cancer compounds comprising screening compounds for activity to inhibit PFK-2 but not PFK.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: July 2, 2002
    Assignee: The Picower Institute for Medical Research
    Inventors: Richard J. Bucala, Jason Chesney, Robert A. Mitchell
  • Antagonism of endothelin actions
    Patent number: 6410007
    Abstract: The mechanism of hypertension following acute NO synthase blockage is via endothelin-mediated vasoconstriction. Thus, NO appears to inhibit endothelin activity by blocking its expression and not as a chronic direct acting vasodilator. Administration of an endothelin antagonist to a patient in a ‘normal’ physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: June 25, 2002
    Assignee: Queen's University at Kingston
    Inventors: James D. Banting, Jeremy P. W. Heaton, Michael A. Adams
  • Methods to assay gene function with viral vectors
    Patent number: 6410257
    Abstract: The present invention provides a conditionally replicating viral vector, methods of making, modifying, propagating and selectively packaging, and using such a vector, isolated molecules of specified nucleotide and amino acid sequences relevant to such vectors, a pharmaceutical composition and a host cell comprising such a vector, the use of such a host cell to screen drugs. The methods include the prophylactic and therapeutic treatment of viral infection, in particular HIV infection, and, thus, are also directed to vital vaccines and the treatment of cancer, in particular cancer of viral etiology. Other methods include the use of such conditionally replicating viral vectors in gene therapy and other applications.
    Type: Grant
    Filed: May 1, 2000
    Date of Patent: June 25, 2002
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Boro Dropulic, Paula Pitha-Rowe
  • Ribozyme treatment of diseases or conditions related to levels of NF-&kgr;B
    Patent number: 6410224
    Abstract: Enzymatic RNA molecules which cleave rel A mRNA.
    Type: Grant
    Filed: December 23, 1996
    Date of Patent: June 25, 2002
    Assignee: Ribozyme Pharmaceuticals, Inc.
    Inventors: Dan T. Stinchcomb, Kenneth G. Draper, James McSwiggen
  • Sugar modified oligonucleotides
    Patent number: 6399754
    Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2′-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.
    Type: Grant
    Filed: August 17, 1998
    Date of Patent: June 4, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventor: Phillip Dan Cook
  • Antisense modulation of expression of tumor necrosis factor receptor-associated factors (TRAFs)
    Patent number: 6399297
    Abstract: Compositions and methods are provided for modulating the expression of tumor necrosis factor receptor-associated factor (TRAF). Antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding TRAF are preferred. Methods of using these compounds for modulation of TRAF expression and for treatment of diseases associated with expression of TRAF are provided.
    Type: Grant
    Filed: October 6, 1998
    Date of Patent: June 4, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brenda F. Baker, Lex M. Cowsert, Brett P. Monia, Xaoxing S. Xu
  • Modulators of the function of FAS receptors and other proteins
    Patent number: 6399327
    Abstract: The present invention provides proteins capable of modulating or mediating the FAS receptor ligand or TNF effect on cells carrying FAS receptor or p55 receptor by binding or interacting with MORT-1 protein, which in turn binds to the intracellular domain of the FAS receptor or to another protein TRADD which binds to the p55 receptor. In addition, peptide inhibitors which interfere with the proteolytic activity of MORT-1-biding proteins having proteolytic activity are provided as well as a method of designing them.
    Type: Grant
    Filed: April 10, 1998
    Date of Patent: June 4, 2002
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: David Wallach, Mark Boldin, Tanya Goncharov, Yury V. Golstev
  • Therapy for &agr;-galactosidase a deficiency
    Patent number: 6395884
    Abstract: A therepeutic method whereby an individual suspected of having an &agr;-galactosidase A deficiency, such as Fabry disease, is treated either with (1) human cells that have been genetically modified to overexpress and secrete human &agr;-gal A, or (2) purified human &agr;-gal A obtained from cultured, genetically modified human cells.
    Type: Grant
    Filed: April 6, 2000
    Date of Patent: May 28, 2002
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Richard F. Selden, Marianne Borowski, Frances P. Gillispie, Carol M. Kinoshita, Douglas A. Treco, Melanie D. Williams
  • Floral homeotic genes for manipulation of flowering in poplar and other plant species
    Patent number: 6395892
    Abstract: Four floral homeotic genes from Poplar are disclosed. The disclosed nucleic acid molecules are useful for producing transgenic plants having modified fertility characteristics, particularly sterility.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: May 28, 2002
    Assignee: The State of Oregon Acting by and through the State Board of Higher Education on Behalf of Oregon State University
    Inventors: Steven H. Strauss, William Rottmann, Amy Brunner, Lorraine Sheppard
  • Compositions and methods for treatment of Hepatitis C virus-associated diseases
    Patent number: 6391542
    Abstract: Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: May 21, 2002
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kevin P. Anderson, Ronnie C. Hanecak, Kazuya Hoshiko, Chikateru Nozaki, Tsukasa Nishihara, Hiroshi Nakatake, Fukusaburo Hamada, Tatsuo Eto, Shinichi Furukawa, Shoji Furasako, Thomas W. Bruice, Walter F. Lima
  • Antisense inhibition of A20 expression
    Patent number: 6387699
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of A20. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding A20. Methods of using these compounds for modulation of A20 expression and for treatment of diseases associated with expression of A20 are provided.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: May 14, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Jacqueline Wyatt
  • NF-AT polypeptides and polynucleotides
    Patent number: 6388052
    Abstract: The invention provides novel polypeptides which are associated with the transcription complex NF-AT, polynucleotides encoding such polypeptides, antibodies which are reactive with such polypeptides, polynucleotide hybridization probes and PCR amplification probes for detecting polynucleotides which encode such polypeptides, transgenes which encode such polypeptides, homologous targeting constructs that encode such polypeptides and/or homologously integrate in or near endogenous genes encoding such polypeptides, nonhuman transgenic animals which comprise functionally disrupted endogenous genes that normally encode such polypeptides, and transgenic nonhuman animals which comprise transgenes encoding such polypeptides.
    Type: Grant
    Filed: March 9, 1998
    Date of Patent: May 14, 2002
    Assignee: Board of Trustees of the Leland Stanford Junior University
    Inventors: Gerald R. Crabtree, Jeffrey P. Northrop, Steffan N. Ho
  • Bidirectional promoters and methods related thereto
    Patent number: 6388170
    Abstract: The present invention comprises artificial nucleic acid constructs comprising a bidirectional promoter having minimal promoter and a common promoter, wherein said minimal promoters is operably linked to said common promoter, in opposite orientation to said common promoter, and 5′ to said common promoter. Those artificial nucleic acid constructs, wherein said bidirectional promoter further comprises at least one gene operably linked to said minimal promoter and said common promoter are preferred.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: May 14, 2002
    Assignee: University of Kentucky Research Foundation
    Inventors: Susheng Gan, Mingtang Xie, Yuehui He
  • Antisense inhibition of clusterin expression
    Patent number: 6383808
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of clusterin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding clusterin. Methods of using these compounds for modulation of clusterin expression and for treatment of diseases associated with expression of clusterin are provided.
    Type: Grant
    Filed: September 11, 2000
    Date of Patent: May 7, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Susan M. Freier
  • Antisense inhibition of cytohesin-1 expression
    Patent number: 6383809
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of cytohesin-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cytohesin-1. Methods of using these compounds for modulation of cytohesin-1 expression and for treatment of diseases associated with expression of cytohesin-1 are provided.
    Type: Grant
    Filed: October 30, 2000
    Date of Patent: May 7, 2002
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Heterologous polypeptides expressed in filamentous fungi, processes for making same, and vectors for making same
    Patent number: 6379928
    Abstract: Novel vectors are disclosed for expressing and secreting heterologous polypeptides from filamentous fungi. Such vectors are used in novel processes to express and secrete such heterologous polypeptides. The vectors used for transforming a filamentous fungus to express and secrete a heterologous polypeptide include a DNA sequence encoding a heterologous polypeptide and a DNA sequence encoding a signal sequence which is functional in a secretory system in a given filamentous fungus and which is operably linked to the sequence encoding the heterologous polypeptide. Such signal sequences may be the signal sequence normally associated with the heterologous polypeptides or may be derived from other sources. The vector may also contain DNA sequences encoding a promoter sequence which is functionally recognized by the filamentous fungus and which is operably linked to the DNA sequence encoding the signal sequence.
    Type: Grant
    Filed: December 10, 1999
    Date of Patent: April 30, 2002
    Assignee: Genencor International, Inc.
    Inventors: Randy Michael Berka, Daniel Cullen, Gregory Lawrence Gray, Kirk James Hayenga, Virgil Bryan Lawlis
  • Chimeric DNA/RNA ribozymes containing propanediol
    Patent number: 6379931
    Abstract: DNA-RNA-(Pr)n-RNA-DNA ribozymes of formula III or IV: 5′ Z-cugaugag-(Pr)n-cgaaa-X 3′  III. 3′X-aaagc-(Pr)n-gaguaguc-Z-R-Z-cugaugag-(Pr)n-cgaaa-X 3′  IV. in which X and Z comprise DNA sequences that base pair with an RNA substrate at positions adjacent to an RNA cleavage site; cugaugag and cgaaa are catalytic RNA sequences; Pr is a spacer residue —P(O)(OH)—O—CH2CH2CH2—O—; and R is a bridging residue —O—CH2—C(CH2OH)(CH3)—CH2—O—. The ribozymes can be made on any DNA synthesizer using phosphoramidite chemistry, and are useful as therapeutic agents for treating viral or endogenous RNA-mediated diseases. Preferred ribozymes target a sequence in the U5 region of HIV-1.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: April 30, 2002
    Assignee: City of Hope
    Inventors: John J. Rossi, Piotr M. Swiderski
  • Transgenic plants or algae expressing an AGP enzyme coupled to a transit peptide
    Patent number: 6379968
    Abstract: The present invention relates to transgenic plants or algae expressing an AGP enzyme coupled to a transit peptide. In particular, the present invention relates to transgenic plants or algae in which the activity of the AGP enzyme or subunit thereof is substantially independent of any level of in vivo 3-phospho-glycerate and any in vivo level of inorganic phosphate and wherein the activity of the AGP enzyme or subunit thereof is not stimulated by fructose-1,6-bisP and is not inhibited by AMP.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: April 30, 2002
    Assignee: Danisco A/S
    Inventor: Peter Poulsen